Collagenase clostridium histolyticum for Dupuytren's contracture
Collagenase clostridium histolyticum for Dupuytren's contracture
复制标题
DOI：
10.1517/14712598.2010.510509
复制
发表时间：
2010-09-01
影响因子：
4.6
通讯作者：
Hentz, Vincent R.
中科院分区：
文献类型：
--
作者：
Desai, Shaunak S.;Hentz, Vincent R.
该领域的重要性：Dupuytren病是一种非恶性的进行性手部疾病，可严重限制手部功能并降低整体生活质量。随着全球预期寿命的增加，这种疾病在所有族裔群体中的发病率似乎都在增加。治疗传统上仍然是手术，很少有有效的非手术选择。然而，随着胶原酶溶组织梭菌的引入治疗Dupuytren挛缩，医生和外科医生可能会提供一种新的，基于办公室的，非手术治疗这种疾病的选择。本综述涵盖的领域：胶原酶治疗Dupuytren病的相关文献；包括其作用机制、安全性、有效性以及最近FDA批准的临床证据。读者将获得什么：通过对PubMed和医药产品许可组织网站的全面审查，获得关于胶原酶的最新信息。带回家的信息：胶原酶治疗Dupuytren挛缩的III期临床试验最近已经完成。满足主要和次要目标，胶原酶已获得FDA批准临床使用。胶原酶现在为Dupuytren病提供了一种非手术治疗选择。虽然短期结果显示胶原酶是安全有效的，但长期反复注射的效果和挛缩复发率还有待研究。
Importance of the field: Dupuytren's disease is a non-malignant, progressive disorder of the hands that can severely limit hand function and diminish overall quality of life. With global life expectancy increasing, the prevalence of this disease appears to be increasing amongst all ethnic groups. Treatment has traditionally remained surgical with few effective, nonsurgical options. However, with the introduction of collagenase clostridium histolyticum to treat Dupuytren's contractures, physicians and surgeons may be provided with a new, office-based, non-surgical option to treat this disease.Areas covered in this review: The literature behind the use of collagenase to treat Dupuytren's disease; including its mechanism of action, safety, efficacy and clinical evidence behind its recent FDA approval.What the reader will gain: The latest information available on collagenase through a comprehensive review of PubMed and the websites of licensing organizations for medicinal products.Take home message: Phase III, clinical trials on collagenase for treatment of Dupuytren's contractures have recently been completed. Meeting primary and secondary objectives, collagenase has obtained FDA approval for clinical use. Collagenase now provides a non-operative option for Dupuytren's disease. Although short-term results show that collagenase is safe and efficacious, long-term effects of repeat injections and contracture recurrence rates have yet to be examined.